David Roth is Chief Medical Officer at Syros Pharmaceuticals, Inc. (SYRS). They have made 1 open-market trade across 1 company since 2023, most recently 2024-11-18.
CIK 0001599014
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| SYRS | 18,875 | $2K |
Shares reported on the most recent Form 4, priced at the 2024-11-04 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| SYRS | SELL | 2024-11-18 | 2024-11-20 | $0.20 | $2K | -13.8% | -31.0% | -32.3% |
| SYRS | SELL · 10b5-1 | 2024-04-03 | 2024-04-05 | $4.95 | $103K | +9.7% | +9.0% | +7.9% |
| SYRS | SELL · 10b5-1 | 2024-04-02 | 2024-04-02 | $4.98 | $747 | +16.4% | +12.3% | +6.5% |
| SYRS | SELL · 10b5-1 | 2023-12-12 | 2023-12-14 | $4.95 | $31K | +68.4% | +66.8% | +49.1% |
| SYRS | SELL · 10b5-1 | 2023-12-06 | 2023-12-08 | $3.95 | $25K | +31.3% | +66.3% | +67.0% |
| SYRS | SELL · 10b5-1 | 2023-07-31 | 2023-08-02 | $3.95 | $29K | +5.4% | +4.3% | -33.1% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.